Metopirone

Metyrapone, the active ingredient in Metopirone, is a cortisol synthesis inhibitor presented as an oral formulation for oral use. It is employed in diagnostic testing of adrenal insufficiency and in the treatment of Cushing's syndrome. GNH USA supplies Metopirone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metopirone acts on adrenal cortisol production pathways and is used in specific endocrine evaluations and therapies. - Adrenal insufficiency (diagnostic testing): helps assess adrenal reserve by measuring cortisol response after inhibition. - Cushing's syndrome (treatment): reduces excess cortisol production in patients with endogenous hypercortisolism. - Hypothalamic‑pituitary‑adrenal axis evaluation: assists in distinguishing ACTH‑dependent from ACTH‑independent disorders.

Metyrapone may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Nausea - Dizziness - Headache - Fatigue - Abdominal discomfort - Mild hypertension

Serious or Rare Side Effects: - Acute adrenal insufficiency - Severe hypertension or hypertensive crisis - Hypokalemia - Allergic skin reactions (rash, urticaria) - Hepatic enzyme elevation

Before initiating Metopirone, clinicians should consider several safety measures. - Monitor cortisol levels: assess endocrine response regularly. - Check electrolytes: watch for potassium disturbances. - Observe blood pressure: hypertension may develop. - Evaluate liver function: use cautiously in hepatic impairment. - Avoid in patients with known hypersensitivity to metyrapone. - Store at room temperature: keep in the original container, protect from moisture.

Metyrapone can alter the metabolism of several co‑administered drugs.

Major Interactions (Avoid): - Ketoconazole: both inhibit steroidogenesis and may cause severe adrenal suppression. - Rifampin: strong enzyme inducer that reduces metyrapone efficacy.

Moderate Interactions (Monitor Closely): - Anticonvulsants (e.g., phenytoin, carbamazepine): may lower plasma levels. - Oral contraceptives: metyrapone can decrease steroid hormone concentrations. - Glucocorticoid replacement therapy: dose adjustments may be required.